Moderna, Inc. (MRNA) shares plummeted 5.01% during Friday's trading session, following the company's update on its cancer drug candidate mRNA-4359 in combination with pembrolizumab at a major oncology conference. The disappointing results led to a significant sell-off, with the stock reaching $25.96 by mid-afternoon.

The biotech company, known for its mRNA technology, presented new data from its phase 1/2 clinical trial of mRNA-4359 plus pembrolizumab. While specific details were not provided, the market reaction suggests that investors were less than enthused about the results. Moderna stated that a 5-year follow-up from the Phase 2 study is expected in 2026, indicating a lengthy timeline for potential drug development and approval.

Despite the negative market reaction, Wolfe Research analyst Alexandria Hammond offered a more optimistic view, suggesting that Moderna was "checking another mark" in its oncology franchise. This implies that while the results may not have met immediate expectations, they could still represent progress in Moderna's broader cancer treatment strategy. However, the market's sharp reaction highlights the challenges and high stakes in the competitive field of cancer immunotherapy.